Drugs / ABBV 324
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06858813 | Apr 2025 → Sep 2030 expected | hepatocellular carcinoma, non-small cell squamous lung carcinoma | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV 324 | “A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer” NCT06858813 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT06858813 ↗ |